Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men
- 1 October 2002
- journal article
- research article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 76 (4) , 780-788
- https://doi.org/10.1093/ajcn/76.4.780
Abstract
Background: Stimulation of energy expenditure (EE) with selective thermogenic β-adrenergic agonists may be a promising approach for treating obesity. Objective: We analyzed the effects of the highly selective human β3-adrenergic agonist L-796568 on 24-h EE, substrate oxidation, and body composition in obese, weight-stable men. Design: In this 2-center, double-blind, randomized, parallel-group study, we measured 24-h EE before and after 28 d of treatment with L-796568 (375 mg/d) or placebo during weight maintenance (ie, without dietary intervention) in nondiabetic, nonsmoking men aged 25–49 y with body mass index (in kg/m2) of 28–35 (n = 10 subjects per treatment group). Results: The mean change in 24-h EE from before to after treatment did not differ significantly between groups (92 ± 586 and 86 ± 512 kJ/24 h for the L-796568 and placebo groups, respectively). The change in 24-h nonprotein respiratory quotient from before to after treatment did not differ significantly between groups (0.009 ± 0.021 and 0.009 ± 0.029, respectively). No changes in glucose tolerance were observed, but triacylglycerol concentrations decreased significantly with L-796568 treatment compared with placebo (−0.76 ± 0.76 and 0.42 ± 0.31 mmol/L, respectively; P < 0.002). Overall, treatment-related changes in body composition were not observed, but higher plasma L-796568 concentrations in the L-796568 group were associated with greater decreases in fat mass (r = −0.69, P < 0.03). Conclusions: Treatment with L-796568 for 28 d had no major lipolytic or thermogenic effect but it lowered triacylglycerol concentrations. This lack of chronic effect on energy balance is likely explained by insufficient recruitment of β3-responsive tissues in humans, down-regulation of the β3-adrenergic receptor–mediated effects with chronic dosing, or both.Keywords
This publication has 30 references indexed in Scilit:
- The effect of an increased free fatty acid concentration on thermogenesis and substrate oxidation in obese and lean menInternational Journal of Obesity, 2001
- Functional assessment of beta adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscleGut, 2000
- ATYPICAL β-ADRENOCEPTORS MEDIATING RELAXATION IN THE HUMAN COLON: FUNCTIONAL EVIDENCE FOR β3-RATHER THAN β4-ADRENOCEPTORSPharmacological Research, 1999
- Differential Regulation of Mouse Uncoupling Proteins among Brown Adipose Tissue, White Adipose Tissue, and Skeletal Muscle in Chronic β3Adrenergic Receptor Agonist TreatmentBiochemical and Biophysical Research Communications, 1998
- Lipolytic effects of conventional β3‐adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4‐adrenoceptorBritish Journal of Pharmacology, 1997
- Distribution of β3-adrenoceptor mRNA in human tissuesEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Anti-obesity and anti-diabetic effects of CL 316, 243, a highly specific β3-adrenoceptor agonist, in yellow KK miceLife Sciences, 1994
- Expression of the β3-adrenergic receptor in human white adipose tissueJournal of Molecular Endocrinology, 1993
- Is the adipocyte β-adrenoceptor a prototype for the recently cloned atypical ‘β3-adrenoceptor?’Trends in Pharmacological Sciences, 1990
- Lactic Acid Assay with L(+)lactic Acid Dehydrogenase from Rabbit MuscleActa Physiologica Scandinavica, 1963